This company is no longer actively trading as an independent public company (delisted, acquired, or ceased operations). This profile is retained for reference.
Core One Labs Inc. is a technology company that licenses its technology to a state-of-the-art production and packaging facility located in Southern California. The Company’s technology produces infused strips (like breath strips) that are not only a safer, healthier option to other forms of delivery but also superior bioavailability of cannabis constituents. Some strips will also include supplemental co-active ingredients such as nutraceuticals, vitamins and peptides. The technology provides a new way to accurately meter the dosage and assure the purity of selected product.
Stock Performance
Core One Labs News 24 articles
- Core One Labs Announces Non-Brokered Private Placement
- Core One Labs : Commends Study Exploring Psychedelics’ Efficacy in Providing Relief for Chronic Pain Conditions
- Core One Labs’ Acquires GMP Drug Inc.: Positioning Itself as a Full Cycle Psychedelics Supply Chain Solution for Clinicians, Researchers and Other Drug Developers
- Core One Labs : Subsidiary Vocan Biotechnologies Achieves Development Milestones
- Core One Labs’ Announces Appointment of BF Borgers CPA PC as Its New Auditor
- Core One Labs Prepares for Commercial Production of API-Grade Psilocybin Plans Initial Production Run at GMP Facility in January
- Core One Labs Takes Next Steps to Prepare for Potential Takeover Opportunities
- European University to Fund Core One Labs Akome Advanced Neurogenesis Stimulation Studies
- Core One Labs Nearing GMP Production as Canada’s Province of Alberta Announces Game Changing Legislation
- Core One Labs Announces Breakthrough with Proprietary Isolation and Purification Method of Psilocybin from Mushrooms; Prepares Patent Application
- Core One Labs Signs Letter of Intent with GMP Manufacturing Partner for Production of Proprietary Psychedelic Compounds
- Core One Labs’ Akome Move Psychedelic Drug Formulations to Next Stage of Development: Initiating Phase 2 Analysis of Therapeutic Potential
- Core One Labs’ Scientists Successfully Complete Breakthrough First Step in Producing API-Grade DMT
- Core One Rolls Out Commercial Sales Strategy for its Revolutionary API Grade Biosynthetic Psilocybin
- Core One Labs Engages in Talks With GMP Manufacturing Partner for Commercial Scale Production of Proprietary Biosynthetic Psilocybin
- Core One Labs’: Akome Achieves Significant Research Milestone with Positive Neurogenesis Stimulation Studies Results
- Core One Labs’ Akome Achieves Another Milestone in Development of its Psychedelic Drug Formulas and Announces Positive Results from Neuro-Pharmacokinetics Studies
- Core One Labs: Vocan Successfully Converts Psilocin Precursor into Psilocybin
- Core One Labs’ Subsidiaries Successfully Produce Psilocin Precursor for Production to Psilocybin
- Core One Labs’ Upgrades to OTCQB Venture Market
- Core One Labs to Investigate Soliciting Investment and Potential Takeover Opportunities
- Core One Labs Acquires Frontier Mycology
- Core One Labs’ Clinics Submit Application to Treat Patient With Psilocybin Psychedelic-Assisted Therapy
- Core One Labs Completes Acquisition of Akome Biotech